What to Expect From Gilead Sciences' Next Quarterly Earnings Report

Core Insights - Gilead Sciences, Inc. is a biopharmaceutical company focused on developing medicines for unmet medical needs, with a market cap of $152.8 billion [1] - The company is expected to announce its fiscal third-quarter earnings for 2025 on October 30, 2023 [1] Financial Performance - Analysts anticipate Gilead to report a profit of $2.15 per share for the upcoming quarter, reflecting a 6.4% increase from $2.02 per share in the same quarter last year [2] - For the full fiscal year, Gilead's EPS is projected to be $8.07, a significant increase of 74.7% from $4.62 in fiscal 2024, with an expected rise to $8.51 in fiscal 2026 [3] Stock Performance - Gilead's stock has outperformed the S&P 500 Index, gaining 43.8% over the past 52 weeks compared to the index's 15.1% increase [4] - The stock also significantly outperformed the Health Care Select Sector SPDR Fund, which experienced a 4.1% decline during the same period [4] Business Drivers - The company's strong performance is attributed to sales growth in HIV treatments, Livdelzi, and Trodelvy, despite declines in HCV and Veklury sales [5] - The approval of lenacapavir enhances Gilead's HIV portfolio, particularly as Truvada faces generic competition, with key products including Biktarvy and Descovy [5] Analyst Sentiment - The consensus opinion on Gilead stock is moderately bullish, with a "Moderate Buy" rating from analysts; 19 out of 29 analysts recommend a "Strong Buy" [7] - The average analyst price target for Gilead is $127.54, indicating a potential upside of 2.8% from current levels [7]